GLP2: An underestimated signal for improving glycaemic control and insulin sensitivity

Journal of Endocrinology

Volumn 229, Issue 2, 2016, Pages R57-R66

  Amato, Antonella ^a   Baldassano, Sara ^a   Mulè, Flavia ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

GLP2; Insulin resistance; Obesity; Type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; GLUCOSE; INSULIN; PROOPIOMELANOCORTIN; GLUCOSE BLOOD LEVEL;

ENERGY ABSORPTION; ENTEROENDOCRINE CELL; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPOTHALAMUS; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL MODEL; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; INSULIN RESISTANCE; LIPID DIET; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; GLUCAGON-LIKE PEPTIDE 2; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MICE; MODELS, BIOLOGICAL; OBESITY; SIGNAL TRANSDUCTION;

EID: 84977653230     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-16-0035     Document Type: Review

References (112)

1. Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, Krarup T Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and nonglucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism 12 323-333. (doi:10.1111/ j.1463-1326.2009.01167.x)
2. Ahrén B 2006 Glucagon secretion in relation to insulin sensitivity in healthy subjects. Diabetologia 49 117-122. (doi:10.1007/s00125-005- 0056-8)
3. Ahrén B, Simonsson E, Scheurink AJ, Mulder H, Myrsen U, Sundler F Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46 97-106. (doi:10.1016/S0026-0495(97)90175-X)
4. Amato A, Baldassano S, Serio R, Mulè F 2009 Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release. American Journal of Physiology: Gastrointestinal and Liver Physiology 296 G678-G684. (doi:10.1152/ajpgi.90587.2008)
5. Amato A, Rotondo A, Cinci L, Baldassano S, Vannucchi MG, Mulè F Role of cholinergic neurons in the motor effects of glucagonlike peptide-2 in mouse colon. American Journal of Physiology: Gastrointestinal and Liver Physiology 299 G1038-G1044. (doi:10.1152/ ajpgi.00282.2010)
6. Angelone T, Filice E, Quintieri AM, Imbrogno S, Amodio N, Pasqua T, Pellegrino D, Mulè F, Cerra MC 2012 Receptor identification and physiological characterization of glucagon-like peptide-2 in the rat heart. Nutrition, Metabolism, and Cardiovascular Diseases 22 486-494. (doi:10.1016/j.numecd.2010.07.014)
7. Asrih M, Jornayvaz FR 2013 Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. Journal of Endocrinology 218 R25-R36. (doi:10.1530/JOE-13-0201)
8. Au A, Gupta A, Schembri P, Cheeseman CI 2002 Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2. Biochemical Journal 367 247-254. (doi:10.1042/bj20020393)
9. Bahrami J, Longuet C, Baggio LL, Li K, Drucker DJ 2010 The glucagonlike peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology 139 857-868. (doi:10.1053/j. gastro.2010.05.006)
10. Baldassano S, Amato A 2014 GLP-2: what do we know? What are we going to discover? Regulatory Peptides 194-195 6-10. (doi:10.1016/j. regpep.2014.09.002)
11. Baldassano S, Liu S, Qu MH, Mulè F, Wood JD 2009 Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro. American Journal of Physiology: Gastrointestinal and Liver Physiology 297 G800-G805. (doi:10.1152/ ajpgi.00170.2009)
12. Baldassano S, Bellanca AL, Serio R, Mulè F 2012 Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2. Journal of Endocrinology 213 277-284. (doi:10.1530/JOE-12-0092)
13. Baldassano S, Amato A, Cappello F, Rappa F, Mulè F 2013 Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet. Journal of Endocrinology 217 11-20. (doi:10.1530/JOE-12-0500)
14. Baldassano S, Rappa F, Amato A, Cappello F, Mulè F 2015 GLP-2 as beneficial factor in the glucose homeostasis in mice fed a high fat diet. Journal of Cellular Physiology 230 3029-3036. (doi:10.1002/ jcp.25039)
15. Baldassano S, Amato A, Caldara GF, Mulè F 2016a Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high fat diet. Endocrine [in press]. (doi:10.1007/s12020-016-0871-3)
16. Baldassano S, Amato A, Rappa F, Cappello F, Mulè F 2016b Influence of endogenous glucagon like peptide-2 on lipid disorders in mice fed a high fat diet. Endocrine Research [in press]. (doi:10.3109/074358 00.2016.1141950)
17. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH 2000 Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47 112-119. (doi:10.1136/gut.47.1.112)
18. Bjerknes M, Cheng H 2001 Modulation of specific intestinal epithelial progenitors by enteric neurons. PNAS 98 12497-12502. (doi:10.1073/ pnas.211278098)
19. Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nature Medicine 18 950-955. (doi:10.1038/nm.2745)
20. Breen DM, Rasmussen BA, Côté CD, Jackson VM, Lam TK 2013 Nutrient-sensing mechanisms in the gut as therapeutic targets for diabetes. Diabetes 62 3005-3013. (doi:10.2337/db13-0523)
21. Bremholm L, Hornum M, Henriksen BM, Larsen S, Holst JJ 2009 Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scandinavian Journal of Gastroenterology 44 314-319. (doi:10.1080/00365520802538195)
22. Brubaker PL 2006 The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Annals of the New York Academy of Sciences 1070 10-26. (doi:10.1196/annals.1317.006)
23. Brubaker PL, Izzo A, Hill M, Drucker DJ 1997a Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. American Journal of Physiology 272 E1050-E1058.
24. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH, Drucker DJ 1997b Circulating and tissue forms of the intestinal growth factor, glucagonlike peptide-2. Endocrinology 138 4837-4843.
25. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, Martines D Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. American Journal of Physiology. Gastrointestinal and Liver Physiology 292 G518-G525. (doi:10.1152/ajpgi.00024.2006)
26. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al. 2007 Metabolic endotoxemia initiates obesity and insulin resi stance. Diabetes 56 1761-1772. (doi:10.2337/db06-1491)
27. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, et al. 2009 Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58 1091-1103. (doi:10.1136/gut.2008.165886)
28. Carlsson LM, Peltonen M, Ahlin S, Anveden A, Bouchard C, Carlsson B, Jacobson P, Lonroth H, Maglio C, Naslund I, et al. 2012 Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. New England Journal of Medicine 367 695-704. (doi:10.1056/ NEJMoa1112082)
29. Cheeseman CI 1997 Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. American Journal of Physiology 273 R1965-R1971.
30. Christensen M, Knop FK, Vilsbøll T, Aaboe K, Holst JJ, Madsbad S, Krarup T 2010 Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regulatory Peptides 163 96-101. (doi:10.1016/j. regpep.2010.05.004)
31. Cinci L, Faussone-Pellegrini MS, Rotondo A, Mulè F, Vannucchi MG GLP-2 receptor expression in excitatory and inhibitory enteric neurons and its role in mouse duodenum contractility. Neurogastroenterology and Motility 23 e383-e392. (doi:10.1111/j.1365- 2982.2011.01750.x)
32. Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE 2012 Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 35 1420-1428. (doi:10.2337/dc11-2289)
33. Crowe S, Turpin SM, Ke F, Kemp BE, Watt MJ 2008 Metabolic remodeling in adipocytes promotes ciliary neurotrophic factormediated fat loss in obesity. Endocrinology 149 2546-2556. (doi:10.1210/en.2007-1447)
34. Cummings DE 2012 Metabolic surgery for type 2 diabetes. Nature Medicine 18 656-658. (doi:10.1038/nm.2773)
35. Dash S, Xiao C, Morgantini C, Connelly PW, Patterson WB, Lewis GF Glucagon-like peptide 2 regulates release of chylomicron from the intestine. Gastroenterology 2 1-10. (doi:10.1053/j. gastro.2014.08.037)
36. de Heer J, Pedersen J, Ørskov C, Holst JJ 2007 The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 50 2135-2142. (doi:10.1007/s00125-007-0761-6)
37. de Meijer VE, Le HD, Meisel JA, Akhavan Sharif MR, Pan A, Nosé V, Puder M 2010 Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism 59 1092-1105. (doi:10.1016/j. metabol.2009.11.006)
38. Delarue J, Magnan C 2007 Free fatty acids and insulin resistance. Current Opinion in Clinical Nutrition and Metabolic Care 10 142-148. (doi:10.1097/MCO.0b013e328042ba90)
39. Donath MY, Burcelin R 2013 GLP-1 effects on islets: hormonal, neuronal, or paracrine? Diabetes Care 36 S145-S148. (doi:10.2337/ dcS13-2015)
40. Drucker DJ, Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 1696-1705. (doi:10.1016/S0140- 6736(06)69705-5)
41. Drucker DJ, Yusta B 2014 Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annual Review of Physiology 76 561-583. (doi:10.1146/annurevphysiol- 021113-170317)
42. Drucker DJ, Erlich P, Asa SL, Brubaker PL 1996 Induction of intestinal epithelial proliferation by glucagon-like peptide 2. PNAS 93 7911-7916. (doi:10.1073/pnas.93.15.7911)
43. El-Jamal N, Erdual E, Neunlist M, Koriche D, Dubuquoy C, Maggiotto F, Chevalier J, Berrebi D, Dubuquoy L, Boulanger E, et al. 2014 Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. American Journal of Physiology: Gastrointestinal and Liver Physiology 307 G274-G285. (doi:10.1152/ajpgi.00389.2012)
44. Ellingsgaard H, Ehses JA, Hammar EB, Van Lommel L, Quintens R, Martens G, Kerr-Conte J, Pattou F, Berney T, Pipeleers D, et al. 2008 Interleukin-6 regulates pancreatic alphacell mass expansion. PNAS 105 13163-13168. (doi:10.1073/ pnas.0801059105)
45. Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-de-Lacerda CA 2010 A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. Journal of Clinical Biochemistry and Nutrition 46 212-223. (doi:10.3164/jcbn.09-83)
46. Fujita Y, Wideman RD, Asadi A, Yang GK, Baker R, Webber T, Zhang T, Wang R, Ao Z, Warnock GL, et al. 2010 Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 138 1966-1975. (doi:10.1053/j.gastro.2010.01.049)
47. Geloneze B, Lima MM, Pareja JC, Barreto MR, Magro DO 2013 Association of insulin resistance and GLP-2 secretion in obesity: a pilot study. Arquivos Brasileiros de Endocrinologia, Metabologia 57 632-635. (doi:10.1590/S0004-27302013000800008)
48. Gjesing AP, Vestmar MA, Jørgensen T, Heni M, Holst JJ, Witte DR, Hansen T, Pedersen O 2011 The effect of PCSK1 variants on waist, waist-hip ratio and glucose metabolism is modified by sex and glucose tolerance status. PLoS ONE 6 e23907. (doi:10.1371/journal. pone.0023907)
49. Guan X 2014 The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 307 R585-R596. (doi:10.1152/ajpregu.00096.2014)
50. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold M, Holst JJ, Hadsell DL, et al. 2006 GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130 150-164. (doi:10.1053/j.gastro.2005.11.005)
51. Guan X, Shi X, Li X, Chang B, Wang Y, Li DP, Chan L 2012 GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility. American Journal of Physiology: Endocrinology and Metabolism E853-E864. (doi:10.1152/ajpendo.00245.2012)
52. Hadjiyanni I, Li KK, Drucker DJ 2009 Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse. Endocrinology 150 592-599. (doi:10.1210/en.2008-1228)
53. Hameed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World Journal of Diabetes 6 598-612. (doi:10.4239/wjd.v6.i4.598)
54. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ 2000 In vivo and in vitro degradation of glucagon like peptide-2 in humans. Journal of Clinical Endocrinology, Metabolism 85 2884-2888. (doi:10.1210/jcem.85.8.6717)
55. Hein GJ, Baker C, Hsieh J, Farr S, Adeli K 2013 GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 62 373-381. (doi:10.2337/db12-0202)
56. Hotamisligil GS 2006 Inflammation and metabolic disorders. Nature 444 860-867. (doi:10.1038/nature05485)
57. Hsieh J, Longuet C, Maida A, Bahrami J, Xu E, Baker CL, Brubaker PL, Drucker DJ, Adeli K 2009 Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 137 997-1005. (doi:10.1053/j.gastro.2009.05.051)
58. Iakoubov R, Lauffer LM, Trivedi S, Kim YI, Brubaker PL 2009 Carcinogenic effects of exogenous and endogenous glucagonlike peptide-2 in azoxymethane-treated mice. Endocrinology 150 4033-4043. (doi:10.1210/en.2009-0295)
59. Janssen P, Vanden Berghe P, Verschueren S, Lehmann A, Depoortere I, Tack J 2011 The role of gastric motility in the control of food intake. Alimentary Pharmacology, Therapeutics 33 880-894. (doi:10.1111/ j.1365-2036.2011.04609.x)
60. Janssen P, Rotondo A, Mulè F, Tack J 2013 Review article: a comparison of glucagon-like peptides 1 and 2. Alimentary Pharmacology, Therapeutics 37 18-36. (doi:10.1111/apt.12092)
61. Kappe C, Zhang Q, Nyström T, Sjöholm A 2014 Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells. Diabetology, Metabolic Syndrome 6 70. (doi:10.1186/1758-5996-6-70)
62. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T 2007 Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type diabetes mellitus. Diabetologia 50 797-805. (doi:10.1007/s00125- 006-0566-z)
63. Koopmann MC, Nelson DW, Murali SG, Liu X, Brownfield MS, Holst JJ, Ney DM 2008 Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats. Journal of Parenteral and Enteral Nutrition 32 254-265. (doi:10.1177/0148607108316198)
64. le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R, Ghatei MA, Patel A, Bloom SR, Aylwin SJ 2010 Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide and intestinal crypt cell proliferation. Annals of Surgery 252 50-56. (doi:10.1097/SLA.0b013e3181d3d21f)
65. Lee SK, Opara EC, Surwit RS, Feinglos MN, Akwari OE 1995 Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice. Pancreas 11 206-211. (doi:10.1097/00006676-199508000-00016)
66. Lim GE, Brubaker PL 2006 Glucagon-like peptide 1 secretion by the L cell. Diabetes 55 S70-S77.
67. Lovshin J, Estall J, Yusta B, Brown TJ, Drucker J 2001 Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. Journal of Biological Chemistry 276 21489-21499. (doi:10.1074/jbc.M009382200)
68. Lovshin JA, Huang Q, Seaberg R, Brubaker PL, Drucker DJ 2004 Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 145 3495-3506. (doi:10.1210/ en.2004-0100)
69. Lund A, Vilsboll T, Bagger JI, Holst JJ, Knop FK 2011 The separate and combined impact of the intestinal secretion in type 2 diabetes hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. American Journal of Physiology: Endocrinology and Metabolism E1038-E1046. (doi:10.1152/ajpendo.00665.2010)
70. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, D'Aleo V, Piro S, Marselli L, et al. 2012 A local glucagonlike peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 3262-3272. (doi:10.1007/s00125-012-2716-9)
71. McArdle MA, Finucane OM, Connaughton RM, McMorrow AM, Roche HM 2013 Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Frontiers in Endocrinology 4 52. (doi:10.3389/ fendo.2013.00052)
72. McDonagh SC, Lee J, Izzo A, Brubaker PL 2007 Role of glial cell-line derived neurotropic factor family receptor a2 in the actions of the glucagon-like peptides on the murine intestine. American Journal of Physiology: Gastrointestinal and Liver Physiology 293 G461-G468. (doi:10.1152/ajpgi.00424.2006)
73. Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ 2006 Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 130 44-54. (doi:10.1053/j. gastro.2005.10.004)
74. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, et al. 2012 Bariatric surgery versus conventional medical therapy for type 2 diabetes. New England Journal of Medicine 366 1577-1585. (doi:10.1056/ NEJMoa1200111)
75. Moffett RC, Vasu S, Thorens B, Drucker DJ, Flatt PR 2014 Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell adaptation to pregnancy. PLoS ONE 9 e96863. (doi:10.1371/ journal.pone.0096863)
76. Moore BA, Peffer N, Pirone A, Bassiri A, Sague S, Palmer JM, Johnson DL, Nesspor T, Kliwinski C, Hornby PJ 2010 GLP-2 receptor agonism ameliorates inflammation and gastrointestinal stasis in murine postoperative ileus. Journal of Pharmacology and Experimental Therapeutics 333 574-583. (doi:10.1124/jpet.109.161497)
77. Moran GW, O'Neill C, McLaughlin JT 2012 GLP-2 enhances barrier formation and attenuates TNFa-induced changes in a Caco-2 cell model of the intestinal barrier. Regulatory Peptides 178 95-101. (doi:10.1016/j.regpep.2012.07.002)
78. Nelson DW, Sharp JW, Brownfield MS, Raybould HE, Ney DM 2007 Localization and activation of GLP-2 receptors on vagal afferents in the rat. Endocrinology 148 1954-1962. (doi:10.1210/en.2006-1232)
79. Nelson DW, Murali SG, Liu X, Koopmann MC, Holst JJ, Ney DM 2008 Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 294 R1175-R1184. (doi:10.1152/ajpregu.00238.2007)
80. Nuzzo D, Picone P, Baldassano S, Caruana L, Messina E, Marino Gammazza A, Cappello F, Mulè F, Di Carlo M 2015 Insulin resistance as common molecular denominator linking obesity to Alzheimer's disease. Current Alzheimer Research 12 723-735. (doi:10.2174/1567205012666150710115506)
81. Ørskov C, Holst JJ, Nielsen OV 1988 Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123 2009-2013. (doi:10.1210/endo-123-4-2009)
82. Ørskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ 2005 GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regulatory Peptides 124 105-112. (doi:10.1016/j.regpep.2004.07.009)
83. Petersen YM, Elnif J, Schmidt M, Sangild PT 2002 Glucagon-like peptide 2 enhances maltase-glucoamylase and sucrase-isomaltase gene expression and activity in parenterally fed premature neonatal piglets. Pediatric Research 52 498-503. (doi:10.1203/00006450- 200210000-00007)
84. Ramsanahie AP, Berger UV, Zinner MJ, Whang EE, Rhoads DB, Ashley SW 2004 Effect of glucagon-like peptide-2 (GLP-2) on diurnal SGLT1 expression. Digestive Diseases and Sciences 49 1731-1737. (doi:10.1007/s10620-004-9561-8)
85. Rotondo A, Amato A, Lentini L, Baldassano S, Mulè F 2011a Glucagonlike peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides 32 60-64. (doi:10.1016/j.peptides.2010.09.028)
86. Rotondo A, Amato A, Baldassano S, Lentini L, Mulè F 2011b Gastric relaxation induced by glucagon-like peptide-2 in mice fed a high-fat diet or fasted. Peptides 32 1587-1592. (doi:10.1016/j. peptides.2011.06.031)
87. Saeidi N, Meoli L, Nestoridi E, Gupta NK, Kvas S, Kucharczyk J, Bonab AA, Fischman AJ, Yarmush ML, Stylopoulos N 2013 Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science 341 406-410. (doi:10.1126/ science.1235103)
88. Sancho V, Trigo MV, Martin-Duce A, Gonz Lez N, Acitores A, Arnés L, Valverde I, Malaisse WJ, Villanueva-Peñacarrillo ML 2006 Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. International Journal of Molecular Medicine 17 1133-1137. (doi:10.3892/ijmm.17.6.1133)
89. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL 2012 Bariatric surgery versus intensive medical therapy in obese patients with diabetes. New England Journal of Medicine 366 1567-1576. (doi:10.1056/ NEJMoa1200225)
90. Schmidt WE, Siegel EG, Creutzfeldt W 1985 Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28 704-707. (doi:10.1007/ BF00291980)
91. Schmidt PT, Hartmann B, Bregenholt S, Hoist JJ, Claesson MH 2000 Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells. Scandinavian Journal of Gastroenterology 35 522-527.
92. Shan CY, Yang JH, Kong Y, Wang XY, Zheng MY, Xu YG, Wang Y, Ren HZ, Chang BC, Chen LM 2013 Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats. Journal of Endocrinology 218 255-262. (doi:10.1530/JOE-13-0184)
93. Shi X, Zhou F, Li X, Chang B, Li D, Wang Y, Tong Q, Xu Y, Fukuda M, Zhao JJ, et al. 2013 Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metabolism 18 86-98. (doi:10.1016/j.cmet.2013.06.014)
94. Shin ED, Estall JL, Izzo A, Drucker DJ, Brubaker PL 2005 Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 128 1340-1353. (doi:10.1053/j.gastro.2005.02.033)
95. Sørensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A 2003 No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. International Journal of Obesity and Related Metabolic Disorders 27 450-456. (doi:10.1038/sj.ijo.0802247)
96. Stephens J, Stoll B, Cottrell J, Chang X, Helmrath M, Burrin DG 2006 Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 290 R283-R289. (doi:10.1152/ajpgi.00275.2005)
97. Sueyoshi R, Woods Ignatoski KM, Okawada M, Hartmann B, Holst J, Teitelbaum DH 2014 Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model. American Journal of Physiology: Gastrointestinal and Liver Physiology 307 G410-G419. (doi:10.1152/ajpgi.00363.2013)
98. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN 1988 Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37 1163-1167. (doi:10.2337/diab.37.9.1163)
99. Talior I, Yarkoni M, Bashan N, Eldar-Finkelman H 2003 Increased glucose uptake promotes oxidative stress and PKC-d activation in adipocytes of obese, insulin-resistant mice. American Journal of Physiology: Endocrinology and Metabolism 285 E295-E302. (doi:10.1152/ajpendo.00044.2003)
100. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N 2000 The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nature Medicine 6 802-807. (doi:10.1038/77535)
101. Tavares W, Drucker DJ, Brubaker PL 2000 Enzymatic- and renaldependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. American Journal of Physiology: Endocrinology and Metabolism 278 E134-E139.
102. Thulesen J, Hartmann B, Ørskov C, Jeppesen PB, Holst JJ, Poulsen SS Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected 125I-GLP-2. Peptides 21 1511-1517. (doi:10.1016/S0196-9781(00)00305-3)
103. Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, Ørskov C, Holst JJ, Poulsen SS 2002 The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regulatory Peptides 103 9-15. (doi:10.1016/S0167-0115(01)00316-0)
104. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ 1997 Intestinal growthpromoting properties of glucagon-like peptide-2 in mice. American Journal of Physiology: Endocrinology and Metabolism 273 E77-E84.
105. Ugleholdt R, Zhu X, Deacon CF, Orskov C, Steiner DF, Holst JJ Impaired intestinal proglucagon processing in mice lack in prohormone convertase 1. Endocrinology 145 1349-1355. (doi:10.1210/en.2003-0801)
106. Valderas JP, Padilla O, Solari S, Escalona M, González G 2014 Feeding and bone turnover in gastric bypass. Journal of Clinical Endocrinology and Metabolism 99 491-497. (doi:10.1210/jc.2013-1308)
107. Vrang N, Hansen M, Larsen PJ, Tang-Christensen M 2007 Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Research 118-126. (doi:10.1016/j.brainres.2007.02.043)
108. Weiss R, D'Adamo E, Santoro N, Hershkop K, Caprio S 2011 Basal alpha-cell up-regulation in obese insulin-resistant adolescents. Journal of Clinical Endocrinology and Metabolism 96 91-97. (doi:10.1210/ jc.2010-1275)
109. Wideman RD, Covey SD, Webb GC, Drucker DJ, Kieffer TJ 2007 A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice. Diabetes 56 2744-2752. (doi:10.2337/db07-0563)
110. Wilson-Pérez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, Stoffers D, Drucker DJ, Pérez-Tilve D, Seeley RJ 2013 Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide-1 receptor deficiency. Diabetes 62 2380-2385. (doi:10.2337/db12-1498)
111. Wøjdemann M, Wettergren A, Hartmann B, Holst JJ 1998 Glucagonlike peptide-2 inhibits centrally induced antral motility in pigs. Scandinavian Journal of Gastroenterology 33 828-832.
112. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ 2000 Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119 744-755. (doi:10.1053/gast.2000.16489)